CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 119 enrolled
Drug / intervention
A-101drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02260180
NCT02260180Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of the Dose-Response Profile of A-101 Topical Solution in Subjects With Seborrheic Keratosis of the Face

Aclaris Therapeutics, Inc.·interventional·Posted Oct 9, 2014·Updated Dec 2, 2020

In Brief

A Phase 2 clinical trial evaluating A-101 for Seborrheic Keratosis. Completed, enrolled 119 participants across 4 sites.

Detailed Summary

The purpose of this study is to evaluate the safety and dose-response of 2 concentrations of A-101 versus a vehicle control in the treatment of seborrheic keratosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeborrheic Keratosis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 9, 2014
Enrollment StartOct 1, 2014
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 11.7 years ago

Interventions

A-101drug

Topical Solution